10-Q: Yield10 Bioscience Reports Q1 2024 Results, Focuses on Sustainable Camelina Products Amidst Financial Challenges

Yield10 Bioscience reported its Q1 2024 financial results, highlighting a focus on commercializing sustainable Camelina products while navigating financial constraints and Nasdaq delisting.

Summary

• Yield10 Bioscience is focused on commercializing sustainable products using Camelina sativa as a platform crop.
• The company is developing Camelina seed oil as a low-carbon intensity feedstock for biofuels and seed oil with high levels of omega-3 fatty acids for aquaculture.
• For the three months ended March 31, 2024, Yield10 reported license revenue of $300,000 from VISION Bioenergy Oilseeds, LLC.
• Research and development expenses decreased by 37% to $1.366 million, primarily due to lower employee compensation and crop trial expenses.
• General and administrative expenses decreased by 19% to $1.374 million as the company sought to lower expenses and conserve cash.
• Net loss for the quarter was $2.472 million, or $4.77 per share, compared to a net loss of $3.782 million, or $18.16 per share, for the same period in 2023.
• The company's cash and cash equivalents totaled $1.597 million as of March 31, 2024.
• Yield10 received $1.211 million in net proceeds from a warrant inducement exercise during the quarter.
• The company has a convertible note payable of $990,000, net of issuance costs, due in August 2024.
• Yield10 anticipates that its present capital resources will not be sufficient to fund its planned operations through the end of the second quarter ending on June 30, 2024, which raises substantial doubt as to the Company's ability to continue as a going concern.
• On May 2, 2024, the company completed a 1-for-24 reverse stock split of its common stock.
• On May 14, 2024, Yield10 received notice from Nasdaq that its common stock would be delisted, effective May 16, 2024, and expects its common stock will commence trading on the OTC Markets Group platform at the open of trading on May 16, 2024 under the symbol YTEN.

Sentiment

Score: 3

Explanation: The sentiment is low due to the company's financial challenges, going concern warning, and Nasdaq delisting. While there are some positive developments, the overall outlook is concerning.

Positives

• The company secured $300,000 in license revenue from VISION Bioenergy Oilseeds, LLC.
• Research and development expenses decreased by 37%, indicating improved cost management.
• General and administrative expenses decreased by 19%, further demonstrating cost control efforts.
• The company received $1.211 million in net proceeds from a warrant inducement exercise, boosting its cash position.

Negatives

• The company reported a net loss of $2.472 million for the quarter.
• The company's auditors have raised substantial doubt about its ability to continue as a going concern.
• Yield10 received notice from Nasdaq that its common stock would be delisted, effective May 16, 2024.
• The company anticipates that its present capital resources will not be sufficient to fund its planned operations through the end of the second quarter ending on June 30, 2024.

Risks

• The company's limited cash resources and accumulated deficit pose a significant risk to its operations.
• Uncertainty about the company's ability to secure additional funding raises concerns about its long-term viability.
• The delisting from Nasdaq could negatively impact the company's stock price, liquidity, and ability to raise capital.
• The company's dependence on government grants and collaborative arrangements exposes it to funding uncertainties.
• The company's success depends on the successful development and commercialization of its Camelina products, which is subject to various risks and uncertainties.

Future Outlook

The company anticipates that its present capital resources will not be sufficient to fund its planned operations through the end of the second quarter ending on June 30, 2024, which raises substantial doubt as to the Company's ability to continue as a going concern. The company is evaluating and pursuing different strategies to obtain the required funding for its operations in the very near term. These strategies may include, but are not limited to: public and private placements of equity and/or debt, licensing and/or collaboration arrangements and strategic alternatives with third parties, or other funding from the government or third parties.

Management Comments

• One of the top priorities of our management is the evaluation and pursuit of different strategies to obtain the required funding for our operations in the very near term.

Industry Context

Yield10's focus on Camelina as a platform crop aligns with the growing demand for sustainable biofuels and omega-3 feedstocks. The company's efforts to develop herbicide-tolerant varieties and improve agronomic performance are crucial for making Camelina an attractive option for farmers. The partnership with VISION Bioenergy Oilseeds, LLC, reflects the industry's interest in low-carbon intensity feedstocks for renewable fuels.

Comparison to Industry Standards

• It's difficult to directly compare Yield10's results to industry standards due to its unique focus on Camelina and its early stage of commercialization.
• However, the company's efforts to develop sustainable feedstocks align with broader industry trends towards renewable fuels and alternative protein sources.
• Comparable companies in the agricultural biotechnology space, such as Ceres, Inc. (now part of Bayer) and Arcadia Biosciences, have also faced challenges in commercializing novel crops.
• Yield10's success will depend on its ability to differentiate its Camelina products and secure partnerships with key players in the biofuel and aquaculture industries.

Stakeholder Impact

• Shareholders will be negatively impacted by the delisting from Nasdaq and the potential for further dilution.
• Employees may face uncertainty due to the company's financial challenges and potential restructuring.
• Customers and partners may be concerned about the company's ability to fulfill its commitments.
• Creditors face increased risk due to the company's going concern warning.

Next Steps

• The company intends to seek approval at its annual shareholder meeting, currently scheduled for June 7, 2024.
• The Company plan to apply for trading on the OTC-QB market.
• The company expects its common stock will commence trading on the OTC Markets Group platform at the open of trading on May 16, 2024 under the symbol YTEN.

Key Dates

Keywords

Yield10 Bioscience, Camelina sativa, Financial Results, Q1 2024, Biofuels, Omega-3, Delisting, Reverse Stock Split, Going Concern, VISION Bioenergy